UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark one) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ____________ to ____________ Commission file number 001-41845 DOMINARI HOLDINGS INC. (Exact name of registrant as specified in its charter) (State or other j ...

Revenue and Loss - For the three months ended June 30, 2023, the company recognized approximately $0.07 million in revenue, primarily from underwriting revenue earned by Dominari Securities[100]. - The company incurred a loss from operations of approximately $9.0 million for the three months ended June 30, 2023, compared to a loss of $2.3 million for the same period in 2022[100]. - For the six months ended June 30, 2023, the company recognized approximately $0.07 million in revenue and incurred a loss from operations of approximately $12.8 million, compared to a loss of $6.1 million in 2022[102]. Expenses - General and administrative expenses increased by approximately $6.8 million, driven by professional fees and increased compensation expenses due to growing operations[101]. - The company is transitioning away from the biotechnology industry into financial services, resulting in a nearly 100% decrease in research and development expenses[101]. Cash Flow - Cash used in operating activities for the six months ended June 30, 2023, was approximately $13.9 million, primarily due to a net loss of approximately $11.7 million[106]. - Net cash used in investing activities for the six months ended June 30, 2023, was approximately $14.7 million, resulting from the purchase of marketable securities of approximately $34.0 million[107]. - Cash used in financing activities for the six months ended June 30, 2023, was approximately $0.9 million, reflecting the cost for the purchase of treasury stock[108]. Financial Position - The company's working capital amounted to approximately $35.7 million as of June 30, 2023, with expectations that cash and cash equivalents will be sufficient for at least the next 12 months[103]. - The company reported a gain of approximately $0.4 million in marketable securities for the three months ended June 30, 2023, a decrease of approximately $2.6 million in losses compared to the prior year[101].

Financial Performance - Net loss attributable to common shareholders for the three months ended March 31, 2023, was $3,762 thousand, compared to a net loss of $6,544 thousand for the same period in 2022, indicating an improvement of approximately 42.2%[12] - Basic and diluted net loss per share improved from $(1.25) in Q1 2022 to $(0.71) in Q1 2023, reflecting a reduction of 43.2%[12] - The net loss for the three months ended March 31, 2023, was $3.762 million, compared to a net loss of $3.535 million for the same period in 2022[21] - For the three months ended March 31, 2023, the company recorded a realized loss of $56,000 and an unrealized loss of $130,000 on marketable securities, with total losses amounting to $65,000[51] - The company reported a net loss of approximately $3.8 million for the three months ended March 31, 2023[128] Cash and Liquidity - Cash and cash equivalents significantly decreased from $33,174 thousand to $9,533 thousand, representing a decline of about 71.3%[10] - The cash and cash equivalents at the end of the period were $9.533 million, down from $70.639 million at the end of the same period in 2022[21] - The company has adequate cash to fund its operations for at least the next twelve months[27] - As of March 31, 2023, the company's working capital was approximately $43.8 million[127] - For the three months ended March 31, 2023, net cash used in operating activities was approximately $4.0 million, compared to $3.8 million for the same period in 2022[128] Expenses - General and administrative expenses rose to $3,833 thousand in Q1 2023, up from $1,787 thousand in Q1 2022, marking an increase of about 114.0%[12] - The company reported total operating expenses of $3,834 thousand for Q1 2023, slightly up from $3,803 thousand in Q1 2022, an increase of approximately 0.8%[12] - The company incurred approximately $2.0 million in increased general and administrative expenses, driven by professional fees and increased compensation expenses[126] - The company recognized other income of approximately $0.07 million for the three months ended March 31, 2023, compared to $0.3 million in the same period in 2022, primarily due to volatility in investment valuations[125] Assets and Liabilities - Total current assets decreased from $50,656 thousand as of December 31, 2022, to $44,771 thousand as of March 31, 2023, a decline of approximately 11.7%[10] - Total liabilities increased from $2,469 thousand as of December 31, 2022, to $5,083 thousand as of March 31, 2023, an increase of approximately 105.5%[10] - Total stockholders' equity decreased from $73,767 thousand as of December 31, 2022, to $69,071 thousand as of March 31, 2023, a decline of about 6.4%[10] Investments - The investment in Kerna Health Inc. was valued at $4.9 million as of March 31, 2023, with no change in value since December 31, 2022[54] - The investment in Tevva Motors was valued at approximately $2.8 million as of March 31, 2023, reflecting no change in value since December 31, 2022[61] - The total value of long-term investments remained unchanged at $23.103 million as of March 31, 2023[54] - The investment in Epic Games was valued at $3.5 million as of March 31, 2023, with no unrealized gain or loss recorded during the period[68] - The investment in SpaceX was valued at approximately $3.7 million as of March 31, 2023, reflecting an unrealized gain of approximately $0.6 million[71] Acquisitions - The company acquired all assets and liabilities of Fieldpoint Private Securities, LLC (FPS) for approximately $3.4 million, with a net cash paid of $1.149 million[21][44] - The FPS acquisition was completed on March 27, 2023, following the approval of the change of ownership by FINRA[44] - The total assets acquired from FPS amounted to $3.784 million, while total liabilities assumed were $360,000, resulting in total net assets of $3.424 million from the acquisition[49] - The company incurred approximately $0.3 million in transaction costs related to the FPS acquisition, which are included in general and administrative expenses[47] Shareholder Actions - The company repurchased 236,630 shares at a cost of approximately $0.9 million, averaging $3.97 per share, under its Share Buyback Program during the three months ended March 31, 2023[102] - The company retired 644,499 shares of treasury stock with an original cost of approximately $3.8 million on March 6, 2023[103] Strategic Focus - Dominari Holdings Inc. continues to focus on shifting its primary operating focus from biotechnology to fintech and financial services[23] - The company is winding down its historical pipeline of biotechnology assets while exploring opportunities in high-growth industries through its subsidiary Aikido Labs[24] - The company did not provide proforma disclosures for the FPS acquisition as it did not significantly impact financial results[50] Internal Controls - The company has not made any changes to its internal control over financial reporting that materially affected its effectiveness during the quarter ended March 31, 2023[136] - The company concluded that its internal control over financial reporting was effective as of March 31, 2023[142]

Part I [Business](index=4&type=section&id=Item%201.%20Business) Dominari Holdings Inc. transitioned from biotechnology to financial services, acquiring a broker-dealer to offer comprehensive financial services - The company shifted its primary focus from biotechnology to financial services in the second half of **2022** to enhance shareholder value[15](index=15&type=chunk) - On **March 27, 2023**, the company completed the acquisition of a registered broker-dealer, to be renamed Dominari Securities, LLC[13](index=13&type=chunk)[16](index=16&type=chunk) - Dominari Securities will offer a broad range of services, including wealth management, asset management, investment banking, and sales and trading[17](index=17&type=chunk)[20](index=20&type=chunk)[25](index=25&type=chunk)[30](index=30&type=chunk) - The company is in the process of winding down its historical biotechnology assets[14](index=14&type=chunk) - As of **December 31, 2022**, the company had **7 full-time and 1 part-time employees**[45](index=45&type=chunk) [Risk Factors](index=10&type=section&id=Item%201a.%20Risk%20Factors) The company faces significant risks from its limited financial services operating history, ongoing losses, internal control weaknesses, market volatility, and extensive regulation - The company has a limited operating history in its new financial services business, making it difficult to evaluate its prospects[47](index=47&type=chunk) Recent Financial Performance | Metric | Value (as of Dec 31, 2022) | | :--- | :--- | | Net Loss | $22.1 million | | Accumulated Deficit | $185.9 million | - As of **December 31, 2022**, management concluded that internal controls over financial reporting were not effective due to a lack of segregation of duties[52](index=52&type=chunk) - The business is highly dependent on market and economic conditions, impacting fees, transaction volume, and trading revenues[53](index=53&type=chunk)[56](index=56&type=chunk) - The company faces intense competition for qualified employees, and the loss of key personnel could harm the business[59](index=59&type=chunk)[60](index=60&type=chunk) - The financial services industry is subject to extensive regulation by the SEC, FINRA, and state regulators, with potential for significant penalties for non-compliance[96](index=96&type=chunk)[97](index=97&type=chunk)[99](index=99&type=chunk) - The company's common stock is at risk of being delisted from The Nasdaq Capital Market if it fails to meet continued listing standards[108](index=108&type=chunk)[111](index=111&type=chunk) [Unresolved Staff Comments](index=21&type=section&id=Item%201b.%20Unresolved%20Staff%20Comments) As a smaller reporting company, Dominari Holdings Inc. is not required to provide information for this item - The company is not required to provide this information as it qualifies as a smaller reporting company[116](index=116&type=chunk) [Properties](index=21&type=section&id=Item%202.%20Properties) The company leases office space in New York, NY, which is considered adequate for current operational needs - The company leases offices in New York, New York, considered sufficient for current needs[117](index=117&type=chunk) [Legal Proceedings](index=21&type=section&id=Item%203.%20Legal%20Proceedings) The company is not aware of any material, active, or pending legal proceedings, aside from ordinary routine litigation - There are no known material, active, or pending legal proceedings against the company, aside from ordinary routine litigation[118](index=118&type=chunk) [Mine Safety Disclosures](index=21&type=section&id=Item%204.%20Mine%20Safety%20Disclosures) This item is not applicable to the company - This section is not applicable[119](index=119&type=chunk) Part II [Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities](index=22&type=section&id=Item%205.%20Market%20for%20Registrant's%20Common%20Equity%2C%20Related%20Stockholder%20Matters%20and%20Issuer%20Purchases%20of%20Equity%20Securities) The company's common stock trades on Nasdaq, with no cash dividends paid, and details provided on share repurchases and equity compensation plans - The company's common stock trades on the Nasdaq Capital Market under the symbol **"DOMH"**, with **4,840,597 shares outstanding** as of **March 20, 2023**[5](index=5&type=chunk)[122](index=122&type=chunk)[123](index=123&type=chunk) - The company has never paid cash dividends and does not plan to in the foreseeable future[124](index=124&type=chunk) Share Repurchases - Q4 2022 | Period | Total Number of Shares Purchased | Average Price Paid Per Share | Value Remaining for Purchase (in thousands) | | :--- | :--- | :--- | :--- | | Oct 2022 | - | - | $2,000 | | Nov 2022 | - | - | $2,000 | | Dec 2022 | 18,200 | $3.1563 | $1,942 | Equity Compensation Plan Information (as of Dec 31, 2022) | Plan Category | Securities to be issued upon exercise | Weighted average exercise price | Securities remaining for future issuance | | :--- | :--- | :--- | :--- | | Approved by security holders | 479,654 | $32.35 | 4,555,144 | [Management's Discussion and Analysis of Financial Condition and Results of Operations](index=23&type=section&id=Item%207.%20Management's%20Discussion%20and%20Analysis%20of%20Financial%20Condition%20and%20Results%20of%20Operations) Dominari shifted to financial services in 2022, reporting a **$22.1 million net loss** due to transition costs and investment losses, with **$48.9 million working capital** for future operations Financial Results Comparison (Fiscal Years) | Metric | 2022 | 2021 | | :--- | :--- | :--- | | Loss from Operations | $(14.4) million | $(9.4) million | | Other (Expense) Income | $(7.8) million | $2.3 million | | Net Loss | $(22.1) million | $(7.2) million | | Net Loss per Share | $(4.91) | $(1.48) | - The **$5.0 million increase** in loss from operations was primarily due to a **$4.0 million increase in G&A expenses**, including **$1.5 million in stock grants**, **$1.5 million in bonuses**, and **$1.6 million in advisory fees** for the business transition[139](index=139&type=chunk) - Other expenses of **$7.8 million in 2022** were mainly due to a **$6.0 million loss on marketable securities** and a **$2.6 million loss on the change in fair value of investments**[139](index=139&type=chunk) Cash Flow Summary (Fiscal Years, $ in millions) | Cash Flow Category | 2022 | 2021 | | :--- | :--- | :--- | | Net Cash Used in Operating Activities | $(10.6) | $(6.6) | | Net Cash Used in Investing Activities | $(14.6) | $(8.9) | | Net Cash (Used in) Provided by Financing Activities | $(7.2) | $78.3 | - The company had working capital of approximately **$48.9 million** as of **December 31, 2022**, and believes it has adequate cash to fund operations for at least the next twelve months[140](index=140&type=chunk)[188](index=188&type=chunk) [Quantitative and Qualitative Disclosures about Market Risk](index=27&type=section&id=Item%207a.%20Quantitative%20and%20Qualitative%20Disclosures%20about%20Market%20Risk) As a smaller reporting company, Dominari Holdings Inc. is not required to provide information for this item - The company is not required to provide this information as it qualifies as a smaller reporting company[145](index=145&type=chunk) [Consolidated Financial Statements and Supplemental Data](index=28&type=section&id=Item%208.%20Consolidated%20Financial%20Statements%20and%20Supplemental%20Data) Consolidated financial statements for 2022 and 2021 are presented, showing a **$22.1 million net loss** in 2022, decreased total assets, and the auditor's critical audit matter on investment valuation - The independent auditor, Marcum LLP, identified the valuation of investments and notes receivable as a critical audit matter for the **2022** financial statements[157](index=157&type=chunk) Consolidated Balance Sheet Highlights (as of Dec 31, $ in thousands) | Account | 2022 | 2021 | | :--- | :--- | :--- | | Cash and cash equivalents | $33,174 | $65,562 | | Total current assets | $50,656 | $90,889 | | Total Assets | $76,236 | $102,656 | | Total Liabilities | $2,469 | $1,061 | | Total Stockholders' Equity | $73,767 | $101,595 | Consolidated Statement of Operations Highlights (Year ended Dec 31, $ in thousands) | Account | 2022 | 2021 | | :--- | :--- | :--- | | Total operating expenses | $14,346 | $9,441 | | Loss from operations | $(14,346) | $(9,441) | | Total other (expenses) income | $(7,761) | $2,270 | | Net loss | $(22,107) | $(7,171) | - In **February 2022**, the company issued **$22 million** in Series O and P Redeemable Convertible Preferred Stock, subsequently redeemed for **$23.1 million** in the second quarter of **2022**[309](index=309&type=chunk)[313](index=313&type=chunk) - The company has significant investments in privately-held companies, including Kerna Health, Tevva Motors, Epic Games, and SpaceX, valued at a total of **$23.1 million** as of **December 31, 2022**[236](index=236&type=chunk) Part III [Changes in and Disagreements with Accountants on Accounting and Financial Disclosure](index=70&type=section&id=Item%209.%20Changes%20in%20and%20Disagreements%20with%20Accountants%20on%20Accounting%20and%20Financial%20Disclosure) On **July 5, 2022**, the company changed its independent auditor from WithumSmith+Brown, PC to Marcum LLP, with no reported disagreements - On **July 5, 2022**, the Audit Committee dismissed WithumSmith+Brown, PC and engaged Marcum LLP as the new independent registered public accounting firm[349](index=349&type=chunk)[352](index=352&type=chunk) - There were no disagreements with Withum on any matter of accounting principles, financial statement disclosure, or auditing scope or procedure during its tenure[351](index=351&type=chunk) [Controls and Procedures](index=70&type=section&id=Item%209A.%20Controls%20and%20Procedures) Management concluded that disclosure controls and internal controls over financial reporting were effective as of **December 31, 2022**, with previously identified material weaknesses remediated - Management concluded that disclosure controls and procedures were effective as of **December 31, 2022**[355](index=355&type=chunk) - Material weaknesses identified in **2021** (lack of segregation of duties and inadequate controls) were remediated as of **December 31, 2022**[357](index=357&type=chunk) - Management concluded that internal controls over financial reporting were effective as of **December 31, 2022**, based on the COSO framework[359](index=359&type=chunk) [Directors, Executive Officers and Corporate Governance](index=73&type=section&id=Item%2010.%20Directors%2C%20Executive%20Officers%20and%20Corporate%20Governance) This section lists directors and executive officers, details independent committee compositions, identifies an audit committee financial expert, and notes the ongoing adoption of a code of ethics Key Executive Officers and Directors | Name | Position | | :--- | :--- | | Robert J. Vander Zanden | Director and Chairman of the Board | | Anthony Hayes | Chief Executive Officer and Director | | Carlos Aldavero | President, Dominari Financial Inc. | | Christopher Devall | Vice President of Operations | - The Audit Committee, comprised of independent directors, includes Timothy Ledwick as the designated **'audit committee financial expert'**[383](index=383&type=chunk) - The Compensation Committee consists of independent directors Kyle Wool (Chairman), Robert J. Vander Zanden, and Robert Dudley[386](index=386&type=chunk) - The company is in the process of adopting a written code of business conduct and ethics[389](index=389&type=chunk) [Executive Compensation](index=76&type=section&id=Item%2011.%20Executive%20Compensation) This section details executive compensation for **2022**, including **CEO Anthony Hayes's $1,693,350 total compensation**, employment agreements, and non-employee director compensation Summary of Executive Compensation for 2022 | Name and Principal Position | Salary ($) | Bonus ($) | Stock Awards ($) | Option Awards ($) | All Other Comp ($) | Total ($) | | :--- | :--- | :--- | :--- | :--- | :--- | :--- | | Anthony Hayes, CEO | 500,000 | 500,000 | 484,888 | - | 208,462 | 1,693,350 | | Darrell Dotson, VP | 317,308 | - | - | - | - | 317,308 | | Christopher Devall, VP of Ops | 125,000 | 100,000 | 47,601 | - | - | 272,601 | | Carlos Aldovero, President | 198,750 | 213,000 | 146,250 | - | 71,589 | 629,589 | - CEO Anthony Hayes's employment agreement provides for a **$500,000 annual salary** and an annual cash bonus of up to **$250,000** based on performance criteria[397](index=397&type=chunk) - Carlos Aldavero's employment agreement includes a base salary of **$450,000 per annum** and a cash signing bonus of **$213,000**[406](index=406&type=chunk) - Non-employee directors receive an annual retainer of **$65,000**, paid in cash, with an additional **$5,000** for the Chairman of the Board[412](index=412&type=chunk) [Security Ownership of Certain Beneficial Owners and Management, and Related Stockholders](index=82&type=section&id=Item%2012.%20Security%20Ownership%20of%20Certain%20Beneficial%20Owners%20and%20Management%2C%20and%20Related%20Stockholders) As of **March 20, 2023**, directors and officers as a group beneficially owned **9.43%** of common stock, with details on individual holdings and preferred stock owners Beneficial Ownership of Common Stock (as of March 20, 2023) | Name of Beneficial Owner | Shares Beneficially Owned | Percentage | | :--- | :--- | :--- | | Anthony Hayes (CEO) | 176,681 | 3.64% | | Kyle Wool (Director) | 197,080 | 4.07% | | All Directors and Officers as a Group (10 persons) | 436,522 | 9.43% | - As of **March 20, 2023**, there were **4,840,597 shares of Common Stock**, **3,825 shares of Series D Preferred Stock**, and **834 shares of Series D-1 Preferred Stock outstanding**[417](index=417&type=chunk) [Certain Relationships and Related Transactions, and Director Independence](index=86&type=section&id=Item%2013.%20Certain%20Relationships%20and%20Related%20Transactions%2C%20and%20Director%20Independence) The Board has a majority of independent directors, and the company engaged Revere Securities, LLC, a firm with ties to a director and the CEO, for investment management - The Board has determined that directors Vander Zanden, Ledwick, Wool, Blattner, and Yu are independent[421](index=421&type=chunk) - The company engaged Revere Securities, LLC, where director Kyle Wool is president, for investment management services, and CEO Anthony Hayes acquired an **8% ownership interest** in Revere[423](index=423&type=chunk) [Principal Accounting Fees and Services](index=86&type=section&id=Item%2014.%20Principal%20Accounting%20Fees%20and%20Services) The company paid **Marcum LLP $91,417** in audit fees for **2022** and **WithumSmith+Brown, PC $41,200** for **2021**, with all services pre-approved by the Audit Committee Auditor Fees | Auditor | Fiscal Year | Audit Fees | | :--- | :--- | :--- | | Marcum LLP | 2022 | $91,417 | | WithumSmith+Brown, PC | 2021 | $41,200 | - The Audit Committee has a policy for pre-approving all audit and permissible non-audit services provided by the principal accountants[427](index=427&type=chunk) Part IV [Exhibits, Consolidated Financial Statements, Schedules](index=88&type=section&id=Item%2015.%20Exhibits%2C%20Consolidated%20Financial%20Statements%2C%20Schedules) This section lists exhibits filed with the Form 10-K, including corporate governance documents, material contracts, and Sarbanes-Oxley Act certifications - This section provides a list of all exhibits filed with the **10-K**, including the Amended and Restated Membership Interest Purchase Agreement for the FPS acquisition[431](index=431&type=chunk)[433](index=433&type=chunk) - Certifications from the Principal Executive Officer pursuant to Sections **302** and **906** of the Sarbanes-Oxley Act of **2002** are included as exhibits[433](index=433&type=chunk) [Form 10-K Summary](index=92&type=section&id=Item%2016.%20Form%2010-K%20Summary) This item is not applicable to the company - This section is not applicable[434](index=434&type=chunk)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark one) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ____________ to ____________ Commission file number 000-05576 AIKIDO PHARMA INC. (Exact name of registrant as specified in its charter) Delaware 52-0849320 ( ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark one) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ____________ to ____________ Commission file number 000-05576 | --- | --- | |--------------------------------------------------------------------|---------------- ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark one) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ____________ to ____________ Commission file number 000-05576 | --- | --- | |--------------------------------------------|--------------------------------------- ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock ($0.0001 par value per share) AIKI The NASDAQ Capital Market FORM 10-K (Mark one) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________ t ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark one) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ____________ to ____________ Commission file number 000-05576 | --- | --- | |--------------------------------------------------------------------------|----- ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark one) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ____________ to ____________ Commission file number 000-05576 AIKIDO PHARMA INC. | --- | --- | |------------------------------------------------------------------ ...